De­spite Al­bert Bourla's com­ments, FDA tells doc­tors not to re-treat with Paxlovid if symp­toms re­bound

Don’t be alarmed: The FDA said Wednes­day that it’s aware some Covid-19 pa­tients may see a reemer­gence of symp­toms af­ter com­plet­ing a treat­ment course of Pfiz­er’s pill Paxlovid.

In some of these cas­es, Covid pa­tients even test­ed neg­a­tive and then pos­i­tive again.

But the agency is stop­ping short of mak­ing any new rec­om­men­da­tions re­gard­ing Paxlovid, and in­stead in­di­rect­ly re­fut­ed what Pfiz­er CEO Al­bert Bourla said on yes­ter­day’s quar­ter­ly earn­ings call, and what an­oth­er ex­pert wrote in one of the New Eng­land Jour­nal of Med­i­cine‘s blogs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER